Press-release for stocks related to treatment for fnctf

Prices are updated after-hours

tags : Treatment symbols : Fnctf

save search

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| -0.62% | O: -0.53% H: 0.0% C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
PHG | $19.98 0.0% 540K

Health Technology

| -3.34% | O: -1.21% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -1.85% | O: -1.19% H: 0.52% C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K

Health Technology

| -0.51% | O: 1.65% H: 2.43% C: 0.87%
reach treatment research market

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| -1.12% | O: -100.0% H: NaN% C: Infinity%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| -2.0% | O: 0.5% H: 0.83% C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M

Health Technology

| -11.79% | O: 2.33% H: 2.28% C: -4.23%
hope treatment pharmaceuticals city for car-t trial

APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS’ SUMMIT
Published: 2024-04-11 (Crawled : 12:00) - apyxmedical.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -1.12% | O: -100.0% H: NaN% C: Infinity%
APYX | $1.325 -3.99% -4.15% 57K

Health Technology

| -7.69% | O: 2.8% H: 5.44% C: 5.44%
renuvion corporation treatment medical apyx

Hyperpigmentation Treatment Market to Reach $10.5 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research
Published: 2024-03-11 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
reach treatment research market

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M

Health Technology

| -17.51% | O: 2.2% H: 1.21% C: -0.85%
tumors authorization treatment application therapeutics

Myopia and presbyopia treatment market size to grow by USD 7.94 billion from 2022 to 2027, Major Vendors include AbbVie Inc., Alcon Inc. and Arctic Vision, Technavio
Published: 2024-02-28 (Crawled : 17:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -5.92% | O: -1.4% H: 0.0% C: -0.01%
BHC | $8.69 1.05% 0.0% 2.9M

Health Technology

| -5.34% | O: 0.11% H: 2.23% C: 0.11%
ALC | $79.55 1.38% -0.25% 1.1M

Health Technology

| -2.01% | O: 4.09% H: 1.72% C: 1.41%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| -6.91% | O: 0.6% H: 0.02% C: -1.03%
abbvie presbyopia treatment market

Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
Published: 2024-02-20 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
glaucoma ocular offering treatment hypertension eye

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Published: 2024-01-25 (Crawled : 12:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K

Health Technology

| -58.33% | O: -31.9% H: 0.61% C: -11.68%
talicia patent treatment grant

Acute Ischemic Stroke Diagnosis and Treatment Market to Reach $9.2 Billion, Globally, by 2032 at 6.1% CAGR: Allied Market Research
Published: 2023-12-14 (Crawled : 01:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -7.34% | O: -1.89% H: 0.0% C: 0.0%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 5.37% | O: 1.19% H: 3.09% C: 1.3%
SYK | $325.43 -0.62% 0.0% 1.8M

Health Technology

| 9.01% | O: 0.16% H: 0.52% C: -0.64%
MDT | $79.48 0.37% -0.29% 6.7M

Health Technology

| -2.95% | O: 1.05% H: 2.38% C: 0.81%
PHG | $19.98 0.0% 540K

Health Technology

| -4.68% | O: 4.96% H: 1.5% C: 0.91%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -3.8% | O: 1.81% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| 1.26% | O: 1.78% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 4.02% | O: 1.21% H: 0.27% C: -0.52%
stroke reach treatment research market

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -0.41% | O: -0.35% H: 0.0% C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M

Health Technology

| 32.71% | O: -0.52% H: 3.73% C: 1.87%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -0.64% | O: -1.09% H: 0.0% C: 0.0%
disease treatment collaboration teva deal

Non-Invasive Aesthetic Treatment Market to Reach $37.4 Billion, Globally, by 2032 at 9.2% CAGR: Allied Market Research
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -13.31% | O: -2.99% H: 0.0% C: 0.0%
aesthetic reach treatment research market

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
Published: 2023-11-27 (Crawled : 23:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -13.31% | O: -2.99% H: 0.0% C: 0.0%
SWTX | $40.075 -5.64% -5.98% 1.4M

Health Technology

| 93.07% | O: 10.74% H: 16.83% C: 7.17%
fda approval tumors treatment therapeutics

Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
Published: 2023-09-29 (Crawled : 00:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
als hope treatment

Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on the Horiz...
Published: 2023-09-29 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
als hope treatment

Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
Published: 2023-09-19 (Crawled : 04:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -4.46% | O: 3.29% H: 0.0% C: 0.0%
cbl-0201 treatment study

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Published: 2023-08-29 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -2.77% | O: 1.76% H: 0.0% C: 0.0%
EGRX | $4.63 3.35% 3.24% 60K

Health Technology

| -71.92% | O: 0.49% H: 3.15% C: 2.79%
ea-114 fda breast positive cancer treatment pharmaceuticals women meeting

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| 0.5% | O: 1.28% H: 0.0% C: 0.0%
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 13.01% | O: -0.31% H: 0.96% C: -1.35%
lynparza japan approved cancer treatment plus

Hoag Introduces New Precision Treatment for Prostate Cancer Patients
Published: 2023-06-27 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
cancer treatment